"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Cadonilimab plus chemotherapy versus PD-1 inhibitor plus chemotherapy as first-line (1L) treatment for advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS 5: A ...

Tevimbra/Ziihera as a first-line treatment for advanced cancers of the stomach, gastroesophageal junction, and esophagus. The ...

A small Italian study suggests a way to safely reduce gastrectomy rates in microsatellite instability-high disease.

Clinicians can help reduce gastric cancer incidence and mortality in high-risk groups through endoscopic screening and surveillance of precancerous conditions, such as gastric intestinal metaplasia ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Please provide your email address to receive an email when new articles are posted on . Over the past 2 decades, detection of early-stage gastric cancer has increased by more than 50%. This finding ...

HLX22 received orphan drug designation, offering incentives like tax credits and market exclusivity to accelerate development for gastric cancer treatment. Phase 2 trial results showed HLX22 improved ...

A 41-year-old woman scheduled for bariatric surgery was unexpectedly found to have early-stage signet ring cell gastric cancer during preoperative evaluation and subsequent sleeve gastrectomy. The ...